Table 2.
Correlation between LOXL2 expression and clinicopathological factors.
| Low LOXL2 (n = 46) | High LOXL2 (n = 124) | P value | |
|---|---|---|---|
| Age (≥65 vs <65 years) | 14/32 | 70/54 | <0.01 |
| Gender (male vs female) | 28/18 | 74/50 | 1 |
| Tumor location (head vs body/tail) | 10/34 | 95/26 | 0.81 |
| CEA (≥5 ng/mL vs <5 ng/mL) | 9/36 | 38/85 | 0.28 |
| CA19-9 (≥100 U/mL vs <100 U/mL) | 24/22 | 80/44 | 0.14 |
| Tumor size (≥32 mm vs <32 mm) | 33/13 | 100/22 | 0.19 |
| Peritoneal washing cytology (positive vs negative) | 8/36 | 19/103 | 0.56 |
| Portal vein invasion (positive vs negative) | 21/25 | 81/43 | 0.02 |
| Perineural invasion (positive vs negative) | 8/38 | 38/86 | 0.12 |
| Lymph node metastasis (positive vs negative) | 30/16 | 99/25 | 0.68 |
| Stage IA/IB/IIA/IIB/IV | 2/0/13/20/11 | 2/2/18/68/34 | 0.17 |
| Recurrence site (peritoneum/liver/local/lung/lymph node/others) | 5/9/13/2/9/1 | 31/34/46/5/19/2 | 0.04 |
| EMT (mesenchymal vs epithelial) | 9/37 | 78/46 | <0.01 |
Abbreviations, CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; EMT, epithelial-to-mesenchymal transition; LOXL2; lysyl oxidase-like protein 2.